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CARDIAC SPECIFIC TRANSGENIC INHIBITION OF 
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The anthracycline doxorubicin (DOX) is widely used as an effective 
antineoplastic drug. Cardiotoxicity leading to congestive heart failure is the 
primary factor limiting the clinical use of DOX. However, although a variety of 
approaches to protect the heart against DOX-induced cardiotoxicity have been 
attempted; treatment to prevent short and long term DOX-induced cardiac 
damage remains limited. Currently, there is no specific therapeutic strategy 
against this severe disease. Cardiac inflammation and myocardial apoptosis is 
known to contribute to DOX-induced cardiomyopathy. The nuclear factor-kappaB 
(NF-KB) is a part of the innate immune system and is involved in cardiac stress 
reactions. Since NF-KB might playa significant role in cardiac inflammatory 
v 
signaling and apoptosis, we investigated whether or not NF-KS is involved in 
DOX-induced cardiotoxicity. 
Methods and results 
Age-matched wild-type (WT), nontransgenic littermates (NTg) and inhibitory 
kappaS transgenic mice (IKS Tg) mice were divided into six groups based on 
whether the mice receive either DOX or vehicle. DOX was injected at a dose of 
7.5 mg/kg intraperitoneally (i.p.) 2 times over 2 wks. Group I, WT (vehicle, n=6); 
group II, NTg (vehicle, n=6); group III, Tg (vehicle, n=6); group IV, WT (DOX, 
n=14); group V, NTg (DOX, n=14); and group VI, Tg (DOX, n=11). Groups I, II 
and III served as control mice and received injections of saline as vehicle. 14 
days after DOX therapy, cardiac function was assessed by echocardiography 
and hemodynamics using a micro conductance Millar catheter. Following 
invasive hemodynamics, the mice were euthanized and heart and lung weights 
were noted and hearts were perfusion fixed for pathology and morphometry. The 
left ventricular (LV) tissue was harvested for myocardial protein expression of 
pro inflammatory cytokines and proapopotic markers. DOX injection in WT and 
NTg mice resulted in significant impairment in LV function as evidenced by a 
decrease in LV ejection fraction (LVEF), LV systolic pressure (LVSP), LV rate of 
pressure development and pressure decay (±dP/dt) and an increase in LV end-
diastolic and end-systolic diameters, LV end-diastolic pressure and LV end-
diastolic volume (LVEDV). Furthermore, WT and NTg mice after DOX therapy 
showed signs of congestive heart failure as evidenced by an increase in lung 
weight and development of pulmonary edema, which was also associated with 
vi 
signs of adverse ventricular remodeling (increase in chamber diameters and 
decrease in wall thickness). In contrast to these findings, the heart weight, 
LVEDP, LV intrinsic diameters, LVEDVand lung weight were reduced, whereas 
the ± dP/dt, LVSP and LVEF were increased towards normal levels in IKB Tg 
group. 
In order to examine the effects of cardiac specific inhibition of NF-KB on 
inflammatory response and myocardial apoptosis, LV samples were analyzed for 
the protein expression of key inflammatory cytokines [tumor necrosis factor-a 
(TNF-a), interleukin-6 (IL-6) and inducible nitric oxide synthase (iNOS)] and 
proapoptotic proteins (Bax and p53) after DOX therapy. In WT and NTg hearts, 
therapy with DOX was associated with an increase in inflammation and 
apoptosis, as indicated by an up-regulation of TNF-a, IL-6, iNOS, Bax and p53. 
In contrast, IKB Tg mice showed decreased expression of proinflammatory 
cytokines and proapoptotic proteins. Furthermore, survival rate was significantly 
higher in IKB Tg mice than in WT and NTg mice 14 days after DOX injection 
(73% vs 43%, P < 0.05). 
Conclusions 
Cardiac specific inhibition of NF-KB improves LV function and attenuates adverse 
cardiac remodeling in DOX-induced cardiomyopathy. These beneficial effects of 
inhibition of NF-KB may be due to the decrease in the development of cardiac 
inflammation and myocardial apoptosis in DOX-induced cardiotoxicity. These 
findings may have important therapeutic implications of NF-KB in DOX-induced 
congestive heart failure. 
VII 
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Doxorubicin (DOX) was first isolated in early 1950s and is considered one of the 
most effective antineoplastic agents used in the treatment of solid and 
hematopoietic tumors. However, this drug has proven to be a double-edged 
sword since it can also cause severe cardiotoxicity leading to a dilated 
cardiomyopathy, which results in congestive heart failure that is usually refractory 
to common medications (1-3). Therefore, several investigators are currently 
focusing their research to better understand the mechanisms underlying DOX's 
cardiotoxicity. This may enable development of therapies, which may potentially 
prevent and/or treat the heart failure it causes. Although the precise cellular 
mechanisms responsible for the cardiotoxic effects of DOX remain enigmatic, it is 
believed that the antitumor activity of DOX is likely to be distinct from the 
mechanism of its cardiotoxicity (4, 5). It has been suggested that the DOX-
induced cardiomyopathy may be due to the formation of reactive oxygen species, 
expression of proinflammatory genes, apoptosis, and altered molecular signaling 
(2, 3, 6). Until to date, taking these various mechanisms into consideration, a 
variety 
of approaches, which were aimed at preventing or mitigating the cardiotoxicity of 
DOX have been tried, but so far, the ability of these treatments to protect the 
heart from damage has not been successful. Therefore, to understand the 
pathogenesis of DOX-induced cardiac dysfunction, inflammation and apoptosis, 
we investigated the activation of NF-KB in myocardium. 
NF-KB, a ubiquitous transcription factor, was first identified as a regulator of the 
expression of the kappa light-chain gene in murine B lymphocytes (7) but has 
subsequently been found in many different cells. NF-KB is found to be activated 
by a wide range of inducers, such as cytokines, ultraviolet irradiation, and 
chemotherapeutic agents including DOX. In quiescent cells, NF-KB is maintained 
as an inactive form in the cytoplasm where it is bound to IKB inhibitor proteins, 
which prevent NF-KB from entering the nuclei. Upon cellular activation by 
extracellular stimuli, IKB is phosphorylated and proteolytically degraded by 
proteases. This proteolytic process causes the release and translocation of NF-
KB complex into the nucleus, where it can mediate gene transcription by binding 
to specific sequences in the promoter regions of its target genes. Products of 
these target genes initiate or regulate inflammatory responses, apoptosis and 
carcinogenesis. NF-KB promotes or inhibits programmed cell death (8, 9). The 
opposing effects of NF-KB are dependent on cell type and/or the nature of stimuli. 
It remains unclear whether NF-KB regulates inflammation and myocardial 
apoptosis in DOX-induced cardiomyopathy. Therefore, we speculated that 
suppression of inflammation and apoptosis may largely rescue DOX-triggered 
2 
cardiotoxicity. In the present study, we induced DOX cardiomyopathy in a novel 
mouse model, which can specifically inhibit NF-KB signaling pathway in the heart 
and examined the effect of NF-KB inhibition on the following: (1) preservation of 
the systolic and diastolic heart dysfunction; (2) mitigation of inflammatory 




BACKGROUND AND LITERATURE REVIEW 
DOX as an Anticancer Agent 
DOX belongs to a group of anthracycline drugs, which was originally isolated 
from the pigment-producing bacterium Streptomyces peucetius in the early 
1950s. DOX is one of the most effective anticancer agents (10) used in the 
treatment of various neoplasms including acute leukemia, Hodgkin's, and non-
Hodgkin's lymphoma, and breast cancer. Although DOX is an effective 
anticancer agent, it can cause tumor cell resistance and cardiotoxicity leading to 
dilated cardiomyopathy and congestive heart failure, which is refractory to 
common medications (11-14). In recent years, the use of higher doses of DOX 
has dramatically increased the incidence of dilated cardiomyopathy. Figure 1 
depicts the chemical structure of DOX in which the side chain terminates with a 
primary alcohol. Although the precise mechanisms of action of DOX on tumor 
cells have not been fully understood, various mechanisms have been suggested 
by investigators such as: generation of reactive oxygen species leading to DNA 
damage and peroxidation of lipids; inhibition of protein synthesis by interacting 
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with DNA; inhibition of topoisomerase II, resulting in apoptosis and DNA 
breakdown; cross-linking and alkylation of DNA, and blocking DNA strand 
separation and helicase activity (15, 16). The critical component of the antitumor 
activity of DOX is by generation of reactive oxygen species and by DNA 
replication. DOX interacts with mitochondrial enzymes via their quinone ring and 
produces huge amount of reactive oxygen species (17, 18). Furthermore, DOX 
can directly act on DNA base pairs, inhibit DNA topoisomerase II, and lead to 
DNA replication (19-21). 
o OH o 
OH 
o OH 
Figure 1: Chemical structure of DOX: DOX consists of a tetra cyclic ring, 
with the sugar daunosamine attached by a glycosidic linkage. Structurally, 
doxorubicin is related to daunorubicin and differs only in hydroxyl group 
substitution (instead of hydrogen) at the alkyl side chain, at position '9' of 
the 'A' ring. 
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Epidemiology and Clinical Features of DOX-induced Cardiomyopathy 
DOX-induced cardiomyopathy is similar to other forms of dilated cardiomyopathy 
characterized by enlarged ventricles, dilation of all chambers, and presence of 
mural thrombi in both ventricles. DOX causes both acute and chronic 
cardiotoxicity. The acute effects occur in approximately 11 % of patients during or 
soon after initiation of DOX treatment and are usually reversible. The symptoms 
include arrhythmias (supraventricular tachycardia and ventricular premature 
beats), hypotension, and nonspecific electrocardiographic changes (11, 22, 23). 
The chronic cardiotoxic effects of DOX occur in approximately 2% of patients, 
and the prognosis is dismal with a mortality rate >50%. In chronic DOX-induced 
dilated cardiomyopathy, the condition is typically irreversible leading to 
congestive heart failure (11, 14). 
Mechanisms of DOX-induced Cardiomyopathy: Antitumor Activity versus 
Cardiotoxicity 
The antitumor activity of DOX is mainly due to initiation of DNA damage via the 
inhibition of topoisomerase II. DOX-induced cardiotoxicity involves multiple other 
mechanisms including oxidative stress, mitochondrial functional impairment, 
cellular necrosis, and induction of apoptosis (2, 16). Therefore, despite the fact 
that the exact mechanism of DOX-induced cardiomyopathy still remains 
unknown, most investigators believe that an increase in oxidative stress and 
generation of reactive oxygen species (24-26), peroxidation of lipids (24, 27, 28), 
and reductions in the levels of antioxidants and sulfhydryl groups (29-31), playa 
6 
crucial role in the pathogenesis of DOX induced cardiomyopathy (24-26, 32). In 
addition, various other mechanisms suggest that DNA breakdown and protein 
synthesis (33-35); release of vasoactive amines (histamine, serotonin and 
catecholamines) (36); alteration in adrenergic activity (37); mitochondrial 
dysfunction (38); changes in Iysosomes (28); alterations in sarcolemmal Ca2+ 
handling by Na+/K+ ATPase and Ca2+-ATPase activities (39) (40); impairment of 
mitochondrial enzymatic activity (41); and production of highly reactive 
peroxynitrate and nitric oxide and inactivation of myofibrillar creatine kinase (42, 
43). Furthermore, DOX also induces apoptosis in vascular smooth muscle cells 
and cardiomyocytes by activating caspases and DNA degradation (44-46), which 
eventually results in cardiomyocyte loss and thus can exacerbate heart failure 
(47-51). Figure 2 shows the proposed mechanisms of interaction between DOX 
and Nuclear Factor - kappaS (NF-KS) in pathogenesis of dilated cardiomyopathy 
and congestive heart failure. 
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D Antioxidant reserve 
D Inflammation Subcellular Remodeling 
D Free radical production 
D Apoptosis 
Figure 2: Proposed mechanisms of NF-KB and DOX-induced 
cardiomyopathy leading to heart failure. DOX is known to increase 
oxidative stress, which in turn leads to increase in inflammation, 
subcellular remodeling and apoptosis via NF-KB dependent mechanism 
that eventually results in progressive dilated cardiomyopathy and 
congestive heart failure. 
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DOX-induced Toxicity - Why does DOX Target Heart? 
As stated earlier, the exact mechanism of DOX-induced cardiotoxicity still 
remains unclear. DOX is a highly lipophilic drug and has a relatively long half-life 
in the body (16, 52). The presence of quinone ring in the DOX makes it prone to 
the generation of free radicals by redox cycling. Under aerobic conditions, a 
single electron reduction in the DOX molecule causes formation of a 
semiquinone free radical, which donates its unpaired electron to oxygen leading 
to the formation of superoxide radical (26, 53). Mizutani et al. show that a 
relatively small amount of DOX is sufficient to catalyze the generation of 
numerous superoxide radicals (54). As cardiomyocytes constantly require high 
energy phosphates and thus rely on oxidative phosphorylation, these cells are 
more prone to apoptosis than any other cell in the body. Also, as cardiac 
myocytes contains low levels of enzyme catalase, and DOX can readily 
inactivate glutathione peroxidase-1 present in these cells, cardiomyocytes are 
further more susceptible to DOX injury (55, 56). Li et al. show that DOX 
decreases protein levels of cytosolic glutathione peroxidase in cardiomyocytes, 
which is responsible for scavenging of free radicals (57). It should also be noted 
that as cardiomyocytes are considered as terminally differentiated cells, any loss 
of these cells due to necrosis or apoptosis results in paucity of contractile 
elements, eventually leading to cardiac dysfunction. Additionally, Singal et al. 
(58) suggests remodeling of subcellular organelles such as sarcolemma, 
mitochondria, sarcoplasmic reticulum and myofibrils causes alteration in 
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intracellular Ca2+ dynamics and leads to contractile dysfunction in the 
cardiomyocytes (58). 
Nuclear Factor - kappaS (NF-KS) 
NF-KB was discovered in 1986 via its interaction with an 11-base pair sequence 
in the immunoglobulin light-chain enhancer in murine B lymphocytes (59). It is a 
widespread dimeric transcription factor that exists in the cytosol complexed to an 
inhibitory kappaB (IKB) monomer. The complex of NF-KB consists of either a p50 
(NF-KB1) or a p52 (NF-KB2) subunit complexed to another protein from the Rei 
group [which includes p65 (ReIA), c-Rel and ReIB] (60, 61). NF-KB is activated by 
various stimuli including ischemia, cytokines, hypoxia, free radicals and oxidants, 
lipopolysaccharide (LPS), activators of protein kinase C, ultraviolet radiation, and 
viruses (60). The activation of NF-KB due to these stimuli translocates NF-KB to 
the nucleus, which in turn binds to specific DNA binding sites (called KB), present 
within the promoter regions of various genes including those encoding p65, IKBa, 
tumor necrosis factor-a (TNF-a), interleukin (IL)-2, IL-6, IL-8, interferon (IFN)-J3, 
inducible nitric oxide synthase (iNOS), and several adhesion molecules (60, 61). 
This activation of NF-KB is controlled by site-specific phosphorylation and 
ubiquitination of IKB proteins that target IKB for proteasome-mediated 
degradation (62). Although, there are currently seven known IKB isoforms (IKBa, 
IKBJ3, IKBy, Bcl-3, IKBE, IKB-R, and IKB-L) (61), only IKBa and IKBJ3 have been 
studied most extensively, and are thought to be the key regulators of NF-KB 
nuclear translocation. Traenckner et al. show that phosphorylation of serine 
10 
residues at positions 32 and 36 is critical for ubiquitination and degradation of 






Dewadatlon of hcB 
by 28S proteasome 
Figure 3: The NF-KB pathway is activated by various pathologic stimuli, 
which leads to phosphorylation of IKB and proteolytic degradation by 
proteases. This proteolytic process causes the release and translocation of 
NF-KB complex into the nucleus, where it can mediate gene transcription 
by binding to specific sequences in the promoter regions of its target 
genes. Products of these target genes initiate or regulate inflammatory 
responses, apoptosis and carcinogenesis. The figure also depicts the 
overexpression of IKBa, which inhibits the process of phosphorylation of 
IKB by IKB kinase thereby inhibiting the NF-KB pathway. 
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Generation of IKBa S32A, S36A transgenic mice with Cardiac-Specific Inhibition 
of NF-KB 
To specifically determine the role of NF-KB in pathophysiologic processes 
requires specific inhibition of the transcription factor in the heart in vivo, which 
thus far has not been possible. As a result, the contribution of NF-KB to 
cardiovascular pathophysiology in the intact animal has been inferred either from 
correlative evidence (e.g., association of NF-KB activation with a certain 
outcome) or by inhibition with pharmacologic agents of limited specificity (64, 65). 
Although there are numerous pharmacologic agents to inhibit NF-KB, which are 
available for in vivo use, none of these agents have sufficient specificity to 
provide conclusive evidence of NF-KB function (64, 65). Therefore, in order to 
determine whether expression of a transdominant mutant IKBa abrogates NF-KB 
activation specifically in the heart, we have created a transgenic mouse with 
cardiac-specific expression of IKBa S32A, S36A (Figure 3) (66). In this mouse model, 
the a-MyHC promoter was chosen to drive the expression of IKBa S32A, S36A since 
this promoter directs high level, cardiac-specific gene expression in a position-
independent, copy-number-dependent manner (67, 68). As demonstrated by 
Dawn et aI., this IKBa S32A, S36A transgenic mouse exhibits normal cardiac 
morphology and histology and the expression of the mutant IKBa completely 
blocks NF-KB activation by both TNF-a and LPS (two important agents, which 
elicits NF-KB activation and orchestrates NF-KB signaling) (68-70). Therefore, 
these mice provide an in vivo system to study and conclusively determine the 
role of NF-KB in specific cardiac pathophysiological states. In this mouse model, 
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a transgene was constructed for the expression in the murine heart of a 
transdominant human IKBa cDNA (with serine residues at positions 32 and 36 
replaced by alanine, IKBa S32A. S36A). The human IKBa S32A. S36A cDNA was 
released from the original plasmid (pSVK3) (71) by restriction digestion with Sma 
I and subcloned between the S.S kb a-MHC promoter and the 736 bp human 
growth hormone polyadenylation sequences (72) (Figure 4). Transgenic mice 
were made by pronuclear microinjection of the isolated purified linear transgene 
into the male pronuclei of fertilized mouse oocytes (FVB/N strain) (73). The 
founder transgenic mice were genotyped by PCR, using a-MHC-specific primer 







[Sal IISma I] [Sma IlSaII] 
heBa. S32A,S36A Hgh 
736kb 
Not! 
Figure 4: Diagrammatic representation of the transgenic promoter 
construct. The 1.1 kb human IKBa cDNA (IKBa S32A, S36A) was subcloned 
between the 5.5 kb a-MyHC promoter and the 736 bp human growth 
hormone (Hgh) polyadenylation signal. The cDNA was released from 
plasmid pSVK3 by excision with Sma I and cloned into the Sal I restriction 
site of the a-MyHC vector. The transgene was excised from the plasmid by 
restriction with Not I and used for pronuclear microinjection. 
13 
Uses of IKBa S32A, S36A transgenic mice 
Although several pharmacologic inhibitors of NF-KB activation are currently 
available, they lack specificity, and thus, do not yield valid results. For example, 
dithiocarbamates are antioxidants and iron chelators (64), and therefore would 
be expected to produce a multitude of effects, including inhibition of other 
transcription factors like AP-1 (74) in addition to inhibition of NF-KB. Peptide 
inhibitors of NF-KB that have been used in isolated cells (75) are not effective in 
vivo. Furthermore, using pharmacologic inhibitors in vivo, it is impossible to 
localize the effect of inhibition of NF-KB activity to a specific organ. The IKBa S32A, 
S36A transgenic mouse provides a novel tool to investigate specifically and 
conclusively the role of NF-KB in cardiac pathophysiology. As a result of the 
cardiac-specific expression of the transgene, these mice enable assessment of 
the role of NF-KB specifically in the heart. Accordingly, the IKBa S32A, S36A 
transgenic mice should be useful not only for signal transduction research, but 
also to verify the utility and efficacy of new therapeutic approaches in modifying 
NF-KB activity and in modulating the effects of TNF-a and LPS in the setting of 
myocardial ischemia-reperfusion injury, heart failure, septic shock, cardiac 





The prognosis of patients with DOX-induced cardiomyopathy and congestive 
heart failure is dismal and mechanisms leading to this cardiotoxicity remain 
elusive. Also, various approaches to protect the heart against this severe cardiac 
damage have been unsuccessful. 
Proposed Concepts 
Although end-stage ischemic cardiomyopathies could be manageable by using 
procedures such as revascularization and therapeutic angiogenesis, non ischemic 
cardiomyopathies can only be treated radically by heart transplantation (76, 77). 
Cardiac transplantation has several limitations such as availability of donors, 
graft rejection and adverse effects of immunosuppressive medications (76, 77). 
DOX is widely used as a broad-spectrum antineoplastic drug in the treatment of 
both solid tumors and leukemia. Unfortunately, despite its broad spectrum 
effectiveness, long-term therapy with DOX is associated with a high incidence of 
a cumulative and irreversible dilated cardiomyopathy followed by congestive 
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heart failure, which is often fatal to the patients (2, 11, 78). The morphology of 
the heart of DOX-induced cardiomyopathy is similar to dilated cardiomyopathy, in 
which progressive heart failure and sudden cardiac death from ventricular 
arrhythmia occur (79). 
Experimental Design 
To address these issues, a series of experiments were designed to test the 
following hypothesis. The experimental protocol is shown in Figure 5. 
day 0 
BSL echocardiography 





1 . Final echocardiography 
2. In vivo Hemodynamics 
3. Pathology & Morphometry 
4. Western Irnmunoblotting: 
Proinflarrmatory cytokines: TNF-a, IL-6, iNOS 
Antiapoptotic: Bax, p53 
Figure 5: Experimental Protocol. WT, NTg and IkB Tg mice were divided 
into six groups based on whether the mice received either DOX or vehicle. 
DOX was injected at 7.5 mg/kg dose intraperitoneally (i.p.) 2 times over 2 
wks. Group I, WT (vehicle); group II, NTg (vehicle); group III, Tg (vehicle); 
group IV, WT (DOX); group \I, NTg (DOX); and group VI, Tg (DOX). 
Echocardiography was performed at baseline and at 2 wks after DOXlsaline 
therapy. At the end of study period (2wks after first DOX dose), after an 
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invasive hemodynamics, heart and lungs were pathologically assessed and 
L V samples were frozen for the expression of proinflammatory cytokines 
and apoptotic proteins. 
Hypothesis 
Sustained over-expression of proinflammatory cytokines provokes the induction 
of cardiomyocyte apoptosis in DOX-induced cardiomyopathy, which contributes 
to adverse ventricular remodeling and cardiac dysfunction eventually progressing 
to congestive heart failure. 
AIM #1: To test the hypothesis that cardiac-specific transgenic inhibition of NF-
KB mitigates doxorubicin-induced adverse ventricular remodeling and 
cardiac dysfunction. 
AIM #2: To test the hypothesis that cardiac-specific transgenic inhibition of NF-
KB reduces the expression of proinflammatory cytokines in 
doxorubicin-induced cardiomyopathy. 
AIM #3: To test the hypothesis that cardiac-specific transgenic inhibition of NF-





Cardiac-Specific Transgenic Inhibition of NF-KB Mitigates Doxorubicin-
induced Adverse Ventricular Remodeling and Cardiac Dysfunction 
AIM #1 ABSTRACT 
Background 
The use of the DOX is associated with adverse cardiac remodeling with impaired 
ventricular function that can progress to congestive heart failure and has 
important implications for survival. In spite of several pharmacologic and surgical 
interventions for cardiomyopathy, many patients continue to experience a 
progressive decline in cardiac function. Therefore, improved methods to 
attenuate ventricular remodeling and function in dilated cardiomyopathy are 
needed. Although NF-KB has been implicated in heart failure due to ischemia and 
cardiac hypertrophy, its role on detrimental cardiac remodeling and cardiac 
dysfunction in DOX-induced cardiomyopathy are unknown. We sought to 
examine if cardiac specific transgenic inhibition of myocardial NF-KB activation 
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could prevent structural cardiac remodeling and mitigate cardiac dysfunction in 
dilated cardiomyopathy due to DOX treatment. 
Methods and Results 
Age-matched wild-type (WT, n=14), nontransgenic liUermates (NTg, n=14) and 
IKB Tg (n=11) mice received intraperitoneal injections of DOX twice over 2 wks 
(total dose of 15 mg/kg BW). Cardiac function and remodeling were assessed 
using echocardiographic techniques and in vivo hemodynamic measurements. 
Saline injected WT, NTg and IKB Tg mice served as controls. At 14 days after 
DOX therapy, WT and NTg mice showed marked increase in heart weight, left 
ventricular (LV) end-diastolic pressure (LVEDP), LV intrinsic diameters, LV end-
diastolic volume (LVEDV) and reduction in rates of pressure development and 
decay (± dP/dt), LV systolic pressure (LVSP) and LV ejection fraction (LVEF). 
WT and NTg mice also showed signs of heart failure as evidenced by an 
increase in lung weight and development of pulmonary edema. The heart weight, 
LVEDP, LV intrinsic diameters, LVEDV and lung weight were reduced, whereas 
the ± dP/dt, LVSP and LVEF were increased towards control levels in IKB Tg 
group compared with WT and NTg groups. Total mortality during 2 wk follow-up 
period averaged 57% in WT and NTg mice and 27% in IKB Tg mice. 
Conclusions 
The results suggest that cardiac specific abrogation of NF-KB in DOX-induced 
cardiomyopathy decreases mortality and has beneficial effects on LV function 
and cardiac remodeling in congestive heart failure. These findings may have 
important therapeutic implications of NF-KB in DOX-induced cardiac dysfunction. 
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INTRODUCTION 
Heart failure induced by DOX has been characterized by bilateral ventricular 
enlargement followed by thinning of the ventricular wall, and reduction in the 
LVEF (80). After DOX treatment, the LVEF measured by echocardiography is 
shown to be decreased from 54% to 35% while the cardiac output decreased 
from 5.6 to 3.9 Llmin in 2 wks. Dilation of the ventricles as evidenced by increase 
in LV end-diastolic and end-systolic diameters (LVEDD and LVESD) has been 
shown to increase by 10% and 30%, respectively (80). In recent years, a growing 
body of evidence indicates the crucial role of NF-KB as a central mediator of 
various cardiac pathologies. Therefore, complete inhibition of this pathway will be 
beneficial in the setting of stress and heart disease. In these lines, several 
investigators have used the classic model of NF-KB activation to develop 
therapeutic strategies that inhibit various steps in the canonical signaling 
cascade. The appreciation of the importance of the NF-KB family of transcription 
factors in cardiac disease has stimulated the development of multiple therapeutic 
strategies based on modifying this signaling pathway. The aim of this study was 
to examine the effects of cardiac specific inhibition of NF-KB activation on the 
improvement of cardiac function and attenuation of adverse cardiac remodeling 
in DOX-induced cardiomyopathy and congestive heart failure. 
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MATERIALS AND METHODS 
Animals 
All animal studies were performed in accordance with the guidelines of the 
National Institutes of Health (NIH) Guide for the Care and Use of Laboratory 
Animals and University of Louisville. Mice were housed in a facility with a 12 
hr/12 hr light/dark cycle and were fed rodent chow and water ad libitum. The 
room was kept specific pathogen-free. Age-matched wild-type (WT), 
nontransgenic littermates (NTg) and IkB Tg mice were divided into six groups 
based on whether the mice receive either DOX or vehicle. We injected a 7.5 
mg/kg dose of DOX intraperitoneally (i.p.) 2 times over 2 wks. Group I, WT 
(vehicle, n=6); group II, NTg (vehicle, n=6); group III, Tg (vehicle, n=6); group IV, 
WT (DOX, n=14); group V, NTg (DOX, n=14); and group VI, Tg (DOX, n=11). 
Groups I, II and III served as control mice and received injections of saline as 
vehicle. 
Echocardiography 
Echocardiography was performed prior to DOX injection (baseline) and at the 
time of sacrifice (2 wks after the first DOX dose). Mice were weighed and 
anesthetized with isoflurane (ISF) inhalation. Induction was performed over 2 
minutes with 3% ISF in 100% O2. Anesthesia was maintained with 1 % ISF in 
100% O2 at a flow rate of 1 Llmin via a small nose cone. The mice were kept on 
a heating pad in a supine position with a slight tilt to the left decubitus position. 
The heating pad temperature was adjusted to maintain mice rectal temperature 
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between 37 and 380 C. The anterior chest was shaved and the mice were placed 
in the left lateral decubitus position. Echocardiographic images were obtained 
using a Philips HOI 5000 SonoCT ultrasound system equipped with a 12-5 MHz 
phased-array probe fitted with a 0.3 cm standoff and a 15-7 MHz broadband 
linear probe. LV structure and function were assessed by previously validated 
two-dimensional, M-mode, and Doppler echocardiographic techniques. 
Echocardiography - Analysis 
Digital images were analyzed off-line by a single blinded observer using the 
ProSolv image analysis software (ProSolv, Inc., Indianapolis, IN). At least three 
consecutive beats were analyzed and averaged for the reported measurement. 
M-mode LV diameter and wall thickness: 
L VEDD and L VESD were measured from M-mode tracings obtained at the mid-
papillary level and analyzed according to the modified American Society of 
Echocardiography standards (posterior wall leading-edge to leading-edge and 
anterior wall trailing-edge to trailing-edge). 
2-D Cross-sectional Anatomy: 
LV areas in diastole and systole were measured using the American Society of 
Echocardiography standards. 
);- Teichholz EDV: EDV was calculated using the Teichholz formula: 
EDV (IJL) = [7/ (2.4+LVEDD)] x (LVEDD3) 
);- L VEF was calculated as: 
EF (%) = [(LVEDD2-LVESD2)/LVEDD2] x 100 
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Hemodynamics 
The hemodynamic studies were performed just before euthanasia (2 wks after 
the first DOX dose). Animals were anaesthetized (thiopental 50 mg/kg; i.p.), 
intubated and artifiCially ventilated. A 1.4 F microconductance pressure catheter 
(Millar-Instruments, Inc., Texas, USA) was inserted into the right carotid artery 
and advanced into the LV under pressure control as described (81). After 
stabilization for 15 mins, the signals were recorded continuously with a 
Powerlab/4SP AID converter (AD Instruments), stored, and displayed on a 
personal computer. The maximal L VSP an L VEDP, maximal slope of systolic 
pressure increment (+dP/dt) and diastolic pressure decrement (-dP/dt) were 
calculated and corrected according to in vitro and in vivo volume calibrations with 
a cardiac pressure-volume analysis program (PVAN 2.9; Millar instruments). 
Pathology and Morphometry 
Animals were euthanized at 2 wks after the first dose of DOX therapy. Following 
euthanasia, the heart was removed, washed in cold PBS, and weighed with an 
analytical balance. Pathologic heart weight was noted. The heart was then 
cannulated via the aorta and retrogradely perfused at a constant perfusion 
pressure equivalent to 100 cm H20. The heart was perfusion-fixed in 10% 
neutral-buffered formalin and was sectioned serially perpendicular to the 
longitudinal axis, processed, and embedded in paraffin. The morphometric 
variables were calculated by computerized planimetry (Image-Pro Plus) of digital 
images of three Masson's trichrome-stained serial sections taken at 0.5 to 1.0 
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mm intervals along the longitudinal axis. The midsection was used to measure 
LV chamber diameter. LV wall thickness was also measured. All anatomical 
variables were corrected according to a uniform sarcomere length. 
Statistical Analysis 
Data are reported as mean ± SEM. Data were measured with a two-way (time 
and group) ANOVA followed by Student's t tests with the Bonferroni correction 
(82). A 'P' value less than 0.05 was considered statistically significant. All 
statistical analyses were performed using the SPSS software (version 8, SPSS, 
Inc., Chicago, IL). Mortality was analyzed using Kaplan Meier survival analysis. 




Survival rates were compared between wr, NTg and IKB Tg mice up to 14 days 
after DOX injection. As a consequence of preserved LV function in IKB Tg mice 
after DOX, survival was significantly higher in IKB Tg mice than in wr and NTg 
mice. Out of 28 mice that received DOX therapy in wr (n=14) and NTg (n=14) 
groups, 8 mice died in wr and 8 mice in NTg groups at the end of 2 wk follow-up 
period, which corresponds to 57% mortality. We lost 3/11 mice during the 2 wk 
period in IKB Tg group. There was no animal loss in the vehicle treated groups of 
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18 mice. The data on mortality, as well as Kaplan Meier Survival plot for all 
groups is shown in Figure 6. 
Figure 6: Survival curves after DOX injection in WT, NTg and IKB Tg mice at 
2 wks after DOX therapy. Survival curves were created by Kaplan-Meier 
method and compared by log-rank test. Percentages of surviving WT, NTg 
and IKB Tg mice were plotted. 
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Clinical Manifestations and Pathologic Changes in Organs after DOX 
Treatment 
wr and NTg mice had clinical signs of congestive heart failure, i.e. lung 
congestion as reflected by the increased lung weight, ventricular chamber 
enlargement, pulmonary edema and ascites. After echocardiography and 
hemodynamic studies, mice were euthanized with a lethal injection of sodium 
pentobarbital (50 mg/kg) intraperitoneally, and heart and lung weights were 
measured in all the groups. Although body weight was the similar in all groups, 
heart and lung weights were less in IKB Tg mice than in wr and NTg mice after 
DOX administration (Figures 7 A and 7B). Gross anatomical examinations at the 
end of the study period showed the hearts of DOX-treated wr and NTg mice 
were dilated and both the atria and ventricles were enlarged and hypertrophic 
(Figure 8). To confirm the improvement of the morphology of the hearts in IKB Tg 
mice, we examined Masson's trichrome-stained serial sections taken at 0.5 to 1.0 
mm intervals along the longitudinal axis at 2 wks after the DOX therapy. As 
shown in Figure 9, hearts in wr and NTg groups showed thin LV walls compared 
with the control hearts, whereas hearts in IKB Tg groups showed thicker LV walls 
than in wr and NTg mice, being a similar morphology to that of a normal heart. 
Thus, we confirmed that DOX induces cardiomyopathy and that inhibition of NF-
KB improved morphology and function of the DOX injured heart. 
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Figure 7: Pathologic heart weight (A) and lung weight (B) in vehicle-treated 
(A), WT OOX-treated (B), NTg DOX-treated (C) and IKB Tg OOX-treated (0) 
mouse heart at 2 wks after OOXlsaline therapy_ The' IKB Tg mice showed 
decrease in heart and lung weights compared to WT and NTg mice after 
DOX treatment. 
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Figure 8: Gross anatomical changes in vehicle-treated (A), WT DOX-treated 
(B), NTg DOX-treated (e) and IKB Tg DOX-treated (D) mouse heart at 2 wks 
after DOXIsaline therapy. The IKB Tg heart exhibits less chamber dilation 




Figure 9: Assessment of LV remodeling. Representative Masson's 
trichrome-stained myocardial sections from vehicle-treated (A), WT OOX-
treated (B), NTg OOX-treated (C) and IKB Tg OOX-treated (0) mice at 2 wks 
after OOXlsaline therapy. The L V cavity is smaller and the ventricular wall 
is thicker in the IKB Tg mice compared with the WT and NTg mice. 
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IKB Tg Mice Are Resistant to DOX-induced Cardiac Dysfunction 
Echocardiography 
Before DOX injection (baseline), all variables of LV function, measured by 
echocardiography, were similar in WT, NTg and IKB Tg groups (Figure 10); 
indicating that the extent of injury sustained during DOX therapy was 
comparable. WT and NTg mice exhibited a progressive deterioration in LVEF 
from baseline to 2 wks; this worsening in LVEF was attenuated in IKB Tg mice, 
resulting in a markedly greater LVEF at 2 wks compared with WT and NTg mice. 
During follow-up, LVEDD and LVEDV increased progressively in all groups, 
consistent with postinfarct LV remodeling (Figure 10). However, in IKB Tg mice 
LVEDV at 2 wks was significantly smaller compared with WT and NTg mice, 
indicating sustained improvement in LV remodeling with NF-KB inhibition (Figure 
10). Shown in Figure 11 are representative two-dimensional and M-mode 
echocardiographic tracings from a WT, NTg and IKB Tg animal at 2 wks after 
DOX treatment. In contrast to the LV wall motion in the control group (Figure 
11A), the waveforms from the WT (Figure 11 B) and NTg (Figure 11 C) animals 
clearly demonstrated blunted anterior and posterior wall motion, consistent with 
decreased EF (P < 0.05), indicating a decrease in myocardial performance in WT 
and NTg mice after DOX treatment. The decrease in the LV wall motion was 
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Figure 10: Quantitative assessment of LV systolic function. 
Echocardiographic measurements of L VEF (A), L VEDV (B), L VEDD (e) and 
L VESV (D) in WT, NTg and IKB Tg mice at baseline and at 2 wks after 
DOXlsaline therapy. The IKB Tg mice showed an improved LVEF and a 
decreased L VEDV at 2 wks after DOX therapy. Also, compared with the WT 






Figure 11: Echocardiographic data. (A-D) Representative 2-dimensional 
and M-mode echocardiographic images from a normal healthy mouse with 
vehicle injection (A), WT DOX-treated (B), NTg DOX-treated (C), and IKB Tg 
DOX-treated (D) mice at 2 wks after DOXlsaline therapy. Compared with the 
WT and NTg hearts, the IKB Tg heart shows a smaller LV cavity and thicker 
anterior wall. Contractile activity in the anterior wall is present in the IKB Tg 
heart and virtually absent in the WT and NTg heart. 
Hemodynamics 
Hemodynamic parameters obtained from the different experimental groups 2 wks 
after DOX injection are shown in Figure 12. WT and NTg mice showed LV 
dysfunction with decreased LVSP, decreased rate of LV pressure development 
(+dP/dt), pressure decay (-dP/dt) and an elevated LVEDP compared to control 
animals. The LVEDP was reduced, whereas the ±dP/dt and LVSP was increased 
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Figure 12: Hemodynamic measurements of LVSP (A), LVEDP (B), +dP/dt (C) 
and -dP/dt (D) in WT, NTg and IKB. Tg mice at 2 wks after DOXlsaline 
therapy. A decrease in L VSP, performance (+dP/dt) and relaxation (-dP/dt) 
were observed in WT and NTg mice. This was improved in IKB Tg mice. 
Data are mean ± SEM. 
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Figure 13: Morphometric assessment of L V anatomy_ Pathologic 
measurements of chamber diameter (A) and wall thickness (B) in WT, NTg 
and IKB Tg mice at baseline and at 2 wks after DOX/saline therapy_ The IKB 
Tg mice showed a significant decrease in L V chamber diameter and an 
increase in L V wall thickness at 2 wks after DOX therapy_ 
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Cardiac Specific Transgenic Inhibition of NF-KB Halts LV Remodeling in 
DOX-induced Dilated Cardiomyopathy: 
By echocardiography, the LVEDD and LVESD were markedly increased in \NT 
and NTg mice after DOX injection, as shown in Figures 10 and 11. However, in 
IKB Tg mice, LV dilatation after DOX therapy was prevented, and LVEDD and 
LVESD were significantly smaller than in \NT and NTg mice. Similar to these 
findings, morphometric assessment of heart sections showed smaller LV 
chamber diameter in IKB Tg mice treated with DOX when compared with \NT and 
NTg groups. Also, wall thickness was significantly improved in IKB Tg mice 
treated with DOX when compared to \NT and NTg mice (Figure 13). 
CONCLUSIONS: 
This study was undertaken to test the beneficial effects of cardiac specific 
transgenic inhibition of NF-KB on LV function and ventricular remodeling in DOX-
induced cardiomyopathy. From the results obtained in this study, the following 
conclusions can be drawn -
1) Cardiomyopathy in mice due to DOX therapy was evidenced by 
decrease in LVSP, increase in LVEDP and LV diameters followed by 
LV dilation. These changes in LV lead to impairment in systolic and 
diastolic function. 
2) In view of observed alterations in cardiac morphology in \NT, NTg and 
IKB Tg hearts, it is suggested that ventricular remodeling, systolic and 
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diastolic dysfunction in CHF due to DOX therapy, may be partly due to 
the NF-KB activation in the failing heart. 
3) Cardiac specific transgenic inhibition of NF-KB significantly decreased 
mortality and improved the LV function and reversed the adverse 
ventricular remodeling due to DOX and such changes may be 




Cardiac-Specific Transgenic Inhibition of NF-KB reduces the Expression of 
Proinflammatory Cytokines in Doxorubicin-induced Cardiomyopathy 
AIM #2 ABSTRACT 
Background 
The NF-KB proteins are known to playa critical role in mounting the immune 
response and in controlling genes of proinflammatory cytokines. The expression 
of innate immune response proteins such as tumor necrosis factor-a (TNF-a), 
interleukin (IL-6) and inducible nitric oxide synthase (iNOS) occurs in the cardiac 
tissue of humans and experimental animals with heart failure. Therefore, due to 
the profound cardiodepressant effects of proinflammatory cytokines, there is a 
well-justified interest to identify the signaling pathways that drive the expression 
of these proteins in cardiomyocytes. 
Methods and Results 
Age-matched wild-type (\NT, n=14), nontransgenic littermates (NTg, n=14) and 
IKB T9 (n=11) mice received intraperitoneal injections of DOX twice over 2 wks 
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(total dose of 15 mg/kg BW). Myocardial protein expression of proinflammatory 
cytokines, TNF-a, IL-6, and iNOS were assessed by Western immunoblotting. At 
14 days after DOX therapy, we found a significant increase in the expression of 
TNF-a, IL-6, and iNOS in NTg mice treated with DOX. This increase in 
expression of TNF-a, IL-6, and iNOS were significantly attenuated by DOX-
treated IKB Tg mice. 
Conclusions 
Cardiac specific inhibition of NF-KB has preventive effects on cardiac 
inflammation induced by DOX. These findings suggest that NF-KB is detrimental 
in DOX-induced inflammatory processes. These insights might have useful 
implications for future studies utilizing NF-KB antagonists for treatment of human 
DOX-induced cardiomyopathy. 
INTRODUCTION 
The activation and translocation of NF-KB to the nucleus is followed by 
transcription of various pro-inflammatory genes, including tumor necrosis factor-a 
(TNF-a), interleukin (IL-6) and inducible nitric oxide synthase (iN OS) (83, 84). 
NF-KB acts on genes for proinflammatory cytokines, chemokines (chemotactic 
cytokines that attract inflammatory cells to sites of inflammation), enzymes that 
generates mediators of inflammation, immune receptors, and adhesion 
molecules that playa crucial role in the initial recruitment of leukocytes to sites of 
inflammation. The activation of NF-KB leads to a coordinated increase in the 
expression of many proinflammatory genes whose products mediate 
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inflammatory and immune responses. Therefore, NF-KB is an obvious target for 
new types of anti-inflammatory treatment. Although various proinflammatory 
cytokines are not constitutively expressed in the normal heart (85, 86), the failing 
heart produces robust quantities of these cytokines that can be found both in the 
heart and in the peripheral circulation of patients with heart failure. Upregulation 
and production of these cytokines represent an intrinsic or an innate stress 
response against myocardial injury (87). When selectively overexpressed in 
hearts of mice, these cytokines effects the development of a dilated 
cardiomyopathy that closely mimics the pathophysiology seen in human failing 
hearts (88, 89). One pathway that appears to playa role in proinflammation in 
dilated cardiomyopathy is the ubiquitous transcription factor NF-KB. Therefore, 
the objective of this study was to investigate the role of cardiac specific inhibition 
of NF-KB in DOX-induced myocardial inflammation. Using a well established 
model of DOX-induced cardiomyopathy and heart failure in mice, we examined 
whether the inflammatory processes associated with DOX-induced 
cardiomyopathy is a result of an increase in the expression of proinflammatory 
cytokines. 
MATERIALS AND METHODS 
Animals 
All animal studies were performed in accordance with the guidelines of the 
National Institutes of Health (NIH) Guide for the Care and Use of Laboratory 
Animals and University of Louisville. Mice were housed in a facility with a 12 
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hr/12 hr light/dark cycle and were fed rodent chow and water ad libitum. The 
room was kept specific pathogen-free. Age-matched wild-type (WT), 
nontransgenic littermates (NTg) and IkB Tg mice were divided into six groups 
based on whether the mice receive either DOX or vehicle. We injected a 7.5 
mg/kg dose of DOX intraperitoneally (Lp.) 2 times over 2 wks. Group I, WT 
(vehicle, n=6); group II, NTg (vehicle, n=6); group III, Tg (vehicle, n=6); group IV, 
WT (DOX, n=14); group V, NTg (DOX, n=14); and group VI, Tg (DOX, n=11). 
Groups I, II and III served as control mice and received injections of saline as 
vehicle. At the end of study period (14 days after first DOX dose), heart was 
removed, the atria and the large vessels were carefully trimmed, and the 
ventricles were separated. The LV (including septum) was dissected and the 
tissue was frozen at -70°C for protein expression of TNF-a, IL-6 and iNOS. 
Preparation of Homogenates and Cytosolic and Membranous Fractions 
Homogenates, cytosolic and membranous proteins of heart tissue was prepared 
as previously described (90-92). Briefly, myocardial samples were homogenized 
for 2 x 10 seconds in buffer A [25 mmolll Tris . HCI (pH 7.5), 0.5 mmolll EDTA, 
0.5 mmolll EGTA, 1 mmolll phenylmethylsulfonyl fluoride, 2 IJmolil leupeptin, 
1 IJmolil pepstatin, 1 IJmolil aprotinin, 10 mmolll NaF, and 100 IJmolil dephostatin] 
as total cellular homogenates. After that, homogenates were centrifuged at 
14,000 g for 15 mins, and the resulting supernatants were collected as cytosolic 
fractions. Pellets were incubated in a lysis buffer (buffer A + 1 % Nonidet P-40) 
for 4 hrs, centrifuged, and the resulting supernatants used as membranous 
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fractions. The protein content in the homogenates, cytosolic, and membranous 
fractions was determined using the Bradford technique (Bio-Rad). 
Western Immunoblotting 
The expression of proteins was assessed using standard SDS-PAGE Western 
immmunobiotting techniques as previously published methods (90-92). Briefly, 70 
I-1g of cytosolic proteins or membranous proteins were electrophoresed on a 
denaturing SDS gel for 2 to 3 hrs. After electrophoresis, the proteins on the gel 
were electrophoretically transferred to nitrocellulose membranes (Bio-Rad) 
overnight at 4°C. Gel transfer efficiency was carefully recorded by making 
photocopies of membranes dyed with reversible Ponceau staining; gel retention 
was determined by Coomassie blue staining as previously described. The 
membranes were incubated in 5% nonfat dry milk in TBST buffer (10 mmolll 
Tris-HCI [pH 7.2], 0.15 molll NaCI, and 0.05% Tween-20) followed by incubation 
with specific primary antibodies (Santa Cruz Biotechnology, Inc). After extensive 
rinsing with TBST buffer, blots were incubated with HRP-conjugated anti-rabbit or 
anti-mouse secondary antibodies and developed with the use of an enhanced 
chemiluminescence system (ECl kit, Amersham). After washing with TBST 
buffer, blots were air-dried and exposed to Kodak films in x-ray cassettes with 
intensifying screens. The signals detected by immunoblotting and the 
corresponding records of Ponceau stains of nitrocellulose membranes were 
quantitated using an image scanning densitometer (Personal PI, Molecular 
Dynamics). Anti TNF-a, anti Il-6 antibodies were purchased from Santa Cruz 
42 
Biotechnology, Inc., and anti iNOS antibodies were purchased from BD 
Transduction Laboratories. 
Statistical Analysis 
Data are reported as means ± SEM as previously described methods (90-92). 
Measurements were analyzed by ANOVA followed by unpaired Student's t tests 
with the Bonferroni correction. In all Western blot analyses, the content of the 
specific protein of interest was expressed as a percentage of the corresponding 
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Figure 14: Western blots of membranous (Panel A) and cytosolic (Panel B) 
fraction of TNF-a protein at 2 wks after DOXlsaline treatment in NTg mice 
compared with IKB Tg mice. Bar graph shows densitometric quantification 
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Figure 15: Western blots of IL-6 (Panel A) and iNOS (Panel B) proteins at 2 
wks after DOXlsaline treatment in NTg mice compared with IKB Tg mice. 
Bar graph shows densitometric quantification from 5 individual hearts per 
group. Data are mean ± SEM. 
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RESULTS 
TNF-a, IL-6 and iNOS protein expression 
Protein expressions of both membranous and cytosolic fractions showed a 
markedly elevated expression of TNF-a after DOX treatment in NTg mice. 
However, these increases in TNF-a were suppressed in IKB Tg mice compared 
with NTg mice after DOX therapy (P < 0.05) (Figure 14). Furthermore, DOX 
injection led to an increased expression of IL-6 and iNOS in NTg mice compared 
to vehicle treated NTg and IKB Tg· mice hearts. Although IKB Tg mice also 
decreased expression of both IL-6 and iNOS compared to NTg mice, the protein 
expression of iNOS did not display a significant difference in comparison to NTg 
mice after DOX therapy (Figure 15 A and 15 B). 
CONCLUSIONS 
NF-KB regulates gene transcription of many pro-inflammatory cytokines (61) and 
myocardial overexpression of NF-KB initiates an inflammatory cascade and 
elevates the expression of TNF-a, IL-6, and iNOS. This study shows an increase 
in the expression of TNF-a, IL-6, and iN OS in the LV of mouse hearts after DOX 
therapy. However, when IKB transgenic mice were treated with DOX, the 
induction of TNF-a, IL-6 and iNOS was significantly reduced. Thus inhibition of 





Cardiac-Specific Transgenic Inhibition of NF-KB reduces Myocardial 
Apoptosis in Doxorubicin-induced Cardiomyopathy 
AIM #3 ABSTRACT 
Background 
Clinical use of DOX is limited by its cardiotoxic effects, which have been shown 
to be due to increased oxidative stress and apoptosis. It is unclear if inhibition of 
NF-KB has the protective effects on myocardial apoptosis induced by DOX. To 
elucidate the possible role of cardiac specific inhibition of NF-KB during the 
development of DOX cardiomyopathy, we studied IKB Tg mice by investigating 
cardiac apoptosis after induction of DOX-induced cardiomyopathy. 
Methods and Results 
Age-matched wild-type (Wf, n=14), nontransgenic littermates (NTg, n=14) and 
IKB Tg (n=11) mice received intraperitoneal injections of DOX twice over 2 wks 
(total dose of 15 mg/kg BW). Myocardial expression of proapoptotic 
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proteins Bax and p53 were assessed by Western blot analysis. At 14 days after 
DOX therapy, we found a significant increase in the expression of both Bax and 
p53 in NTg mice treated with DOX. This increase in expression of Bax and p53 
were attenuated by DOX-treated IKB Tg mice. 
Conclusions 
Cardiac specific inhibition of NF-KB has preventive effects on myocardial 
apoptosis induced by DOX, which is probably associated with inhibiting binding 
activity of NF-KB and further regulating apoptosis-related protein expression and 
translation, and inhibiting myocardial apoptosis. These findings suggest that NF-
KB is detrimental in DOX-induced cardiomyopathy in that it mediates apoptosis. 
These insights might have useful implications for future studies utilizing NF-KB 
antagonists for treatment of DOX cardiomyopathy. 
INTRODUCTION 
Apoptosis (also known as programmed cell death), is a highly conserved 
evolutionary event that is crucial for normal development and cell homeostasis. It 
is well accepted paradigm that cardiomyocyte apoptosis could playa key role in 
the aggravation of heart failure (49, 93). Recent evidence from both in vitro and 
in vivo studies demonstrate that exposure to DOX can trigger cardiomyocyte 
apoptosis and that this mode of cell death represents the predominant form of 
myocyte injury seen in this toxicity (44, 94). Furthermore, morphological features 
of hearts from patients with DOX-induced cardiomyopathy suggest that myocyte 
cell death may be mediated at least in part through an apoptotic process (58). 
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Therefore, the objective of this study was to investigate the antiapoptotic role of 
cardiac specific inhibition of NF-KB in DOX-induced myocardial apoptosis. Using 
an established model of DOX-induced cardiomyopathy and heart failure in mice, 
we examined whether the myocyte loss associated with DOX-induced 
cardiomyopathy is a result of an increase in the incidence of apoptosis. Protein 
expression of apoptosis regulatory products such as Bax and p53 were 
examined. 
MATERIALS AND METHODS 
Animals 
All animal studies were performed in accordance with the guidelines of the 
National Institutes of Health (NIH) Guide for the Care and Use of Laboratory 
Animals and University of Louisville. Mice were housed in a facility with a 12 
hr/12 hr light/dark cycle and were fed rodent chow and water ad libitum. The 
room was kept specific pathogen-free. Age-matched wild-type (WT), 
nontransgenic littermates (NTg) and IkB Tg mice were divided into six groups 
based on whether the mice receive either DOX or vehicle. We injected a 7.5 
mg/kg dose of DOX intraperitoneally (i.p.) 2 times over 2 wks. Group I, WT 
(vehicle, n=6); group II, NTg (vehicle, n=6); group III, Tg (vehicle, n=6); group IV, 
WT (DOX, n=14); group V, NTg (DOX, n=14); and group VI, Tg (DOX, n=11). 
Groups I, II and III served as control mice and received injections of saline as 
vehicle. At the end of study period (14 days after first DOX dose), heart was 
removed, the atria and the large vessels were carefully trimmed, and the 
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ventricles were separated. The LV (including septum) was dissected and the 
tissue was frozen at -70°C for protein expression of Bax and p53. 
Preparation of Homogenates and Cytosolic and Membranous Fractions 
Homogenates, cytosolic and membranous proteins of heart tissue was prepared 
as previously described (90-92). Briefly, myocardial samples were homogenized 
for 2 x 10 seconds in buffer A [25 mmol/l Tris . HCI (pH 7.5), 0.5 mmol/l EOTA, 
0.5 mmol/l EGTA, 1 mmol/l phenylmethylsulfonyl fluoride, 2 j..Imol/l leupeptin, 
1 j..Imol/l pepstatin, 1 j..Imol/l aprotinin, 10 mmol/l NaF, and 100 j..Imol/l dephostatin] 
as total cellular homogenates. After that, homogenates were centrifuged at 
14,000 9 for 15 mins, and the resulting supernatants were collected as cytosolic 
fractions. Pellets were incubated in a lysis buffer (buffer A + 1 % Nonidet P-40) 
for 4 hrs, centrifuged, and the resulting supernatants used as membranous 
fractions. The protein content in the homogenates, cytosolic, and membranous 
fractions was determined using the Bradford technique (Bio-Rad). 
Western Immunoblotting 
The expression of proteins was assessed using standard SOS-PAGE Western 
immmunobiotting techniques as previously published methods (90-92). Briefly, 70 
j..Ig of cytosolic proteins or membranous proteins were electrophoresed on a 
denaturing SOS gel for 2 to 3 hrs. After electrophoresis, the proteins on the gel 
were electrophoretically transferred to nitrocellulose membranes (Bio-Rad) 
overnight at 4°C. Gel transfer efficiency was carefully recorded by making 
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photocopies of membranes dyed with reversible Ponceau staining; gel retention 
was determined by Coomassie blue staining as previously described. The 
membranes were incubated in 5% nonfat dry milk in TBST buffer (10 mmol/L 
Tris-HCI [pH 7.2], 0.15 mol/L NaCl, and 0.05% Tween-20) followed by incubation 
with specific primary antibodies (Santa Cruz Biotechnology, Inc). After extensive 
rinsing with TBST buffer, blots were incubated with HRP-conjugated anti-rabbit or 
anti-mouse secondary antibodies and developed with the use of an enhanced 
chemiluminescence system (ECL kit, Amersham). After washing with TBST 
buffer, blots were air-dried and exposed to Kodak films in x-ray cassettes with 
intensifying screens. The signals detected by immunoblotting and the 
corresponding records of Ponceau stains of nitrocellulose membranes were 
quantitated using an image scanning densitometer (Personal PI, Molecular 
Dynamics). Anti-Bax, and anti-p53 antibodies were purchased from Santa Cruz 
Biotechnology, Inc. 
Statistical Analysis 
Data are reported as means ± SEM as previously described methods (90-92). 
Measurements were analyzed by ANOVA followed by unpaired Student's t tests 
with the Bonferroni correction. In all Western blot analyses, the content of the 
specific protein of interest was expressed as a percentage of the corresponding 
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Figure 16: Western blots of Bax (Panel A) and p53 (Panel B) protein at 2 
wks after DOXlsaline treatment in NTg mice compared with IKB Tg mice. 
Bar graph shows densitometric quantification from 5 individual hearts per 
group. Data are mean ± SEM. 
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RESULTS 
Attenuation of Bax and p53-mediated apoptosis by cardiac specific 
inhibition of NF-KB 
As shown in Figure 16A, the cardiac protein expression of the proapoptotic 
protein Bax was significantly increased in DOX-treated NTg mice when 
compared with healthy sham controls. Cardiac specific inhibition of NF-KB led to 
a suppression of DOX-induced Bax over expression. Furthermore, we examined 
the changes in protein expression of another proapoptotic factor p53 in NTg mice 
and IKB Tg mice with or without DOX treatment. Protein expression of p53 was 
significantly increased after DOX administration in NTg mice. Although the 
upregulation of p53 was partially prevented by IKB Tg mice, the value did not 
reach statistical significance (Figure 16B). 
CONCLUSIONS 
In the present study, we determined a significant induction of myocardial 
apoptosis following DOX administration in mice, which correlated with abnormal 
expression and translation of proapoptotic proteins Bax and p53. Our results 
showed that cardiac specific inhibition of NF-KB protects myocardium from 
apoptosis by inhibiting NF-KB activation in DOX-induced cardiomyopathy, and 
further regulating expression, and translation of apoptosis-related genes Bax and 
p53. As it is well documented that apoptosis may contribute to cardiomyocyte 
loss and structural changes accompanied by up-regulation of the proapoptotic 
Bcl-2 family member Bax (95), we examined this protein in mice after DOX 
53 
therapy and found a DOX-mediated increase in the cardiac protein expression of 
Bax which was reduced by cardiac specific inhibition of NF-KB. Furthermore, 
DOX-induced apoptosis in cardiomyocytes and endothelial cells is more likely 
attributable to H20 2 production (44, 45), and there is increasing evidence 
connecting p53 to intracellular oxidant formation (96, 97). Also, activation of p53 
may directly induce activation of Bax gene, which contains a p53 binding site. 
Since both superoxide and H202 induce p53, we conducted further studies to 
detect the protein expression of p53 in DOX-treated hearts. Although the precise 
mechanisms of DOX-induced cardiotoxicity remain elusive, there is increasing 
evidence that DOX exposure can trigger cardiomyocyte apoptosis, and that this 
type of cell death represents the predominant form of myocyte damage seen in 
this setting (98). These results suggest that DOX induces myocardial apoptosis 
through activation of NF-KB in mice and NF-KB activation requires IKBa 
degradation. Therefore, regulation and control of NF-KB activation may be a 
powerful therapeutic strategy for reducing DOX-induced myocardial apoptosis. 
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CHAPTER VII 
SUMMARY AND FUTURE DIRECTIONS 
Summary of Findings 
In this study, we have shown for the first time that NF-KB contributes to systolic 
and diastolic cardiac dysfunction, adverse ventricular remodeling, cardiac 
inflammation and apoptosis in experimental DOX-induced cardiomyopathy. In 
agreement with other investigators, WT and NTg mice treated with DOX were 
found to display severe systolic and diastolic LV dysfunction, resulting in 
impaired cardiac function as assessed by echocardiography and invasive 
hemodynamics (99-101). In IKB Tg mice treated with DOX, global LV function as 
indexed by EF, LVSP, LVEDP, and ±dP/dt, was improved as a result of 
enhanced systolic and diastolic performance. In the present study, IKB Tg mice 
also showed lower production of proinflammatory cytokines and less activation of 
proapoptotic proteins after DOX than did WT and NTg mice. Consequently, 
survival rate was higher in IKB Tg mice compared with WT and NTg mice. This 
study provides direct evidence of the involvement of NF-KB mediated signaling 
pathways in DOX-induced cardiomyopathy. One possible mechanism for 
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such a protective effect of NF-KB inhibition is that IKBa expression would directly 
inhibit NF-KB activation, resulting in attenuation of the inflammatory response and 
subsequent myocardial damage, because the expression of many cytokines, 
including TNF-a, IL-6, and iNOS, is regulated by NF-KB activation. These 
cytokines are not constitutively expressed in the normal heart. Upregulation and 
production of these cytokines represent an intrinsic or innate stress response 
against myocardial injury (102, 103). In this investigation, we found that TNF-a, 
IL-6, and iNOS levels decreased noticeably in IKB Tg mice compared with wr 
and NTg mice, further indicating that IKBa overexpression attenuates 
inflammatory response mediated by DOX-induced cardiomyopathy. 
As inflammation might also be associated with induction of apoptosis and as 
TNF-a induces increase in reactive oxygen species production and oxidative 
stress in cardiomyocytes and lead to apoptosis (49, 104), we further investigated 
the expression of proapoptotic proteins Bax and p53 in mice hearts after DOX 
therapy. Since cardiomyocytes are terminally differentiated cells, any loss of 
these cells due to cell death can have critical functional consequences (105). In 
agreement with in vitro and in vivo studies using myocytes, we also found a 
marked up-regulation of the pro-apoptotic protein p53 14 days after DOX 
administration in our model (106, 107). This effect was blunted in IKB Tg mice, 
suggesting that NF-KB contributes to pro-apoptotic activation in DOX-induced 
cardiomyopathy. Furthermore, to investigate possible mechanisms, which may 
lead to attenuated apoptosis in DOX-treated IKB Tg mice, we measured the 
expression of protein Bax, which is a pivotal regulator of mitochondrial apoptosis. 
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The Bax content of IKB Tg mice were significantly decreased when compared to 
wr and NTg mice suggesting protection from apoptosis due to NF-KB deficiency. 
In summary, the effects of DOX-induced cardiomyopathy included cardiac 
dysfunction, detrimental cardiac remodeling, inflammatory response, and 
apoptosis leading to LV dysfunction. NF-KB deficiency attenuated these 
mechanisms known to be critical for the development of DOX-induced heart 
failure. Our data demonstrate a relevant role of NF-KB in the development of this 
disease under experimental conditions. We have shown the preservation of 
cardiac function, increase in survival rate, and attenuation of myocardial 
apoptosis after DOX in IKB Tg mice. These findings strongly implicate that DOX 
induces myocardial apoptosis through activation of NF-KB in mice and NF-KB 
activation require IKBa degradation. 
Future Directions 
In clinical settings, the typical time course of DOX-induced cardiac toxicity is over 
years after multiple low dose treatments. As such, these temporal differences as 
well as other differences between rodents and humans do not allow our results to 
be directly extrapolated to the clinical arena (52, 108, 109). However, further 
clinical trials and basic research will have to verify this concept and furthermore, 
it needs to be elucidated whether or not NF-KB inhibition counteracts with the 
oncological effect of DOX. In these lines, we need better understanding of the 
molecular mechanisms underlying DOX-induced cardiac toxicity. Aside from 
mechanistic aspects, the present investigations suggest the cardioprotective role 
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of NF-KB inhibition in DOX-induced cardiomyopathy, which may be of therapeutic 
benefit for patients receiving DOX. Thus, cardiac specific NF-KB inhibition might 
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